Allogene Therapeutics Inc.

The capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir

Building a sustainable ecosystem requires more than just scientific excellence—it demands a coordinated approach to manufacturing, capital access, and talent development. The Centre for Commercializat

An increasingly popular antigen in hematology-oncology as well as solid tumor oncology is CD70, with a number of players developing therapies to target it. But Pfizer believes its PF-08046040, acquire

Cytokinetics, Inc. CEO Robert Blum has maintained since the company reported positive topline Phase III results for the cardiac myosin inhibitor aficamten in obstructive hypertrophic cardiomyopathy (